down arrow

Marinus Pharmaceuticals, Inc.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals: Major
  • ISIN: US56854Q2003
USD
0.55
0.00 (0.00%)

Feb 12

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

0.000.00

52 Week

0.221.96
Valuation
Technical
Day's Volume

CASH

0

Shareholding (Sep 2024)

FII

11.78%

Held by 48 FIIs

DII

41.53%

Held by 37 DIIs

Promoter

16.78%

How big is Marinus Pharmaceuticals, Inc.?

22-Jun-2025

As of Feb 12, Marinus Pharmaceuticals, Inc. has a market capitalization of 30.37 million, with net sales of 31.47 million and a net profit of -140.50 million over the last four quarters. As of December 2023, the company reported shareholder's funds of 16.77 million and total assets of 170.91 million.

Market Cap: As of Feb 12, Marinus Pharmaceuticals, Inc. has a market capitalization of 30.37 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Marinus Pharmaceuticals reported net sales of 31.47 million and a net profit of -140.50 million.<BR><BR>Balance Sheet Snapshot: As of December 2023, the company reported shareholder's funds of 16.77 million and total assets of 170.91 million.

Read More

What does Marinus Pharmaceuticals, Inc. do?

22-Jun-2025

Marinus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for epilepsy and neuropsychiatric disorders. As of September 2024, it reported net sales of $9 million and a net loss of $24 million, with a market cap of $30.37 million.

Overview:<BR>Marinus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for epilepsy and neuropsychiatric disorders, operating within the Pharmaceuticals: Major industry and classified as a micro-cap company.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 9 Million (Quarterly Results - Sep 2024) <BR>Most recent Net Profit: -24 Million (Quarterly Results - Sep 2024) <BR>Market cap: USD 30.37 Million (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 91.65% <BR>Debt Equity: -0.79 <BR>Return on Equity: 207.58% <BR>Price to Book: -0.46<BR><BR>Contact Details:<BR>Address: 5 Radnor Corporate Center Suite 500, 100 Matsonford Rd RADNOR PA : 19087 <BR>Tel: 1 484 8014670 <BR>Fax: 1 302 6555049 <BR>Website: http://www.marinuspharma.com/

Read More

Should I buy, sell or hold Marinus Pharmaceuticals, Inc.?

22-Jun-2025

Who are in the management team of Marinus Pharmaceuticals, Inc.?

22-Jun-2025

As of March 2022, the management team of Marinus Pharmaceuticals, Inc. includes Chairman Nicole Vitullo, CEO Scott Braunstein, and several independent directors: Charles Austin, Enrique Carrazana, Michael Dougherty, Elan Ezickson, and Seth Fischer. They oversee the company's strategic direction and operations.

As of March 2022, the management team of Marinus Pharmaceuticals, Inc. includes the following individuals:<BR><BR>- Ms. Nicole Vitullo, Chairman of the Board<BR>- Dr. Scott Braunstein, President, Chief Executive Officer, and Director<BR>- Mr. Charles Austin, Director<BR>- Dr. Enrique Carrazana, Independent Director<BR>- Mr. Michael Dougherty, Independent Director<BR>- Mr. Elan Ezickson, Independent Director<BR>- Mr. Seth Fischer, Independent Director<BR><BR>This team is responsible for overseeing the company's strategic direction and operations.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
1

Risky - Not traded in last 10 days

  • The stock is trading risky as compared to its average historical valuations
  • Over the past year, while the stock has generated a return of 0%, its profits have fallen by -3.4%
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals: Major

stock-summary
Market cap

USD 30 Million (Micro Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

91.65%

stock-summary
Debt Equity

-0.79

stock-summary
Return on Equity

207.58%

stock-summary
Price to Book

-0.46

Revenue and Profits:
Net Sales:
9 Million
(Quarterly Results - Sep 2024)
Net Profit:
-24 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
64.33%
0%
64.33%
6 Months
-54.92%
0%
-54.92%
1 Year
-94.55%
0%
-94.55%
2 Years
-91.98%
0%
-91.98%
3 Years
-95.26%
0%
-95.26%
4 Years
-96.33%
0%
-96.33%
5 Years
-93.83%
0%
-93.83%

Marinus Pharmaceuticals, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Icon
No Recent News for the Company
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
100.58%
EBIT Growth (5y)
-186.75%
EBIT to Interest (avg)
-35.66
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.79
Sales to Capital Employed (avg)
0.34
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
-0.46
EV to EBIT
-0.68
EV to EBITDA
-0.68
EV to Capital Employed
-6.07
EV to Sales
2.65
PEG Ratio
NA
Dividend Yield
91.65%
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
Negative BV
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
Bearish
Bullish
Bollinger Bands
Mildly Bearish
Mildly Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Bearish
Dow Theory
Bullish
Bullish
OBV
No Trend
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Sep 2024stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 37 Schemes (29.9%)

Foreign Institutions

Held by 48 Foreign Institutions (11.78%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Sep'24 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Sep 2024 is 16.44% vs 217.39% in Sep 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Sep 2024 is 26.67% vs -145.02% in Sep 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Sep'24",
        "Sep'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "8.50",
          "val2": "7.30",
          "chgp": "16.44%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-20.90",
          "val2": "-31.50",
          "chgp": "33.65%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "3.80",
          "val2": "4.20",
          "chgp": "-9.52%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-24.20",
          "val2": "-33.00",
          "chgp": "26.67%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-2,468.10%",
          "val2": "-4,312.60%",
          "chgp": "184.45%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'23",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2023 is 21.57% vs 66.67% in Dec 2022",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2023 is -614.14% vs 79.96% in Dec 2022",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'23",
        "Dec'22",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "31.00",
          "val2": "25.50",
          "chgp": "21.57%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-130.90",
          "val2": "-112.10",
          "chgp": "-16.77%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "16.90",
          "val2": "10.70",
          "chgp": "57.94%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-141.40",
          "val2": "-19.80",
          "chgp": "-614.14%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-4,243.00%",
          "val2": "-4,426.90%",
          "chgp": "18.39%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Sep'24 - YoYstock-summary
Sep'24
Sep'23
Change(%)
Net Sales
8.50
7.30
16.44%
Operating Profit (PBDIT) excl Other Income
-20.90
-31.50
33.65%
Interest
3.80
4.20
-9.52%
Exceptional Items
0.00
0.00
Consolidate Net Profit
-24.20
-33.00
26.67%
Operating Profit Margin (Excl OI)
-2,468.10%
-4,312.60%
184.45%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in quarter ended Sep 2024 is 16.44% vs 217.39% in Sep 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Sep 2024 is 26.67% vs -145.02% in Sep 2023

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'23stock-summary
Dec'23
Dec'22
Change(%)
Net Sales
31.00
25.50
21.57%
Operating Profit (PBDIT) excl Other Income
-130.90
-112.10
-16.77%
Interest
16.90
10.70
57.94%
Exceptional Items
0.00
0.00
Consolidate Net Profit
-141.40
-19.80
-614.14%
Operating Profit Margin (Excl OI)
-4,243.00%
-4,426.90%
18.39%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2023 is 21.57% vs 66.67% in Dec 2022

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2023 is -614.14% vs 79.96% in Dec 2022

All Annual Resultsstock-summary
stock-summaryCompany CV
About Marinus Pharmaceuticals, Inc. stock-summary
stock-summary
Marinus Pharmaceuticals, Inc.
Pharmaceuticals: Major
Marinus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical-stage product candidate, ganaxolone, is a modulator being developed in various dose forms, including intravenous, oral capsule and oral liquid, intended to provide more treatment options to adult and pediatric patient populations in both acute and chronic care settings. Ganaxolone acts on the GABAA receptor, a target in the brain known for both anti seizure and anti anxiety effects through positive allosteric modulation. The Company is developing ganaxolone for multiple epilepsy and other neuropsychiatric indications, including adjunctive, or add-on, therapy for the treatment of drug-resistant focal onset seizures; status epilepticus; Fragile X Syndrome, and PCDH19 pediatric epilepsy.
Company Coordinates stock-summary
Company Details
5 Radnor Corporate Center Suite 500, 100 Matsonford Rd RADNOR PA : 19087
stock-summary
Tel: 1 484 8014670
stock-summary
http://www.marinuspharma.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."